Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series

BMC Nephrology

Table 1 Demographic and clinical characteristics of NS patients (N = 44) treated with Acthar gel

NS etiology	Age ± SD, years	Gender, n (%) female	Race/ethnicity, n (%) White	Previous IST/CT, n (%) yes
FSGS (n = 15)	53.3 ± 12.9	7 (47)	12 (80)	12 (80)
iMN (n = 11)	53.6 ± 18.9	4 (36)	10 (91)	10 (91)
IgAN (n = 5)	35.0 ± 8.4	2 (40)	4 (80)	1 (20)
DN (n = 4)	54.0 ± 19.9	2 (50)	4 (100)	0
MLN (n = 2)	37.5 ± 4.9	1 (50)	0	2 (100)
MCD (n = 2)	33.5 ± 13.4	2 (100)	2 (100)	2 (100)
FGN (n = 1)	63.0	0	1 (100)	1 (100)
MPGN (n = 1)	22.0	1 (100)	1 (100)	0
Other^a (n = 3)	55.7 ± 6.1	2 (67)	2 (67)	2 (67)

Abbreviations: CT cytotoxic therapy, DN diabetic nephropathy, FGN fibrillary glomerulonephritis, FSGS idiopathic focal segmental glomerulosclerosis, IgAN IgA nephropathy, iMN idiopathic membranous nephropathy, IST immunosuppressive therapy, MCD minimal change disease, MLN membranous lupus nephritis (class V), MPGN membranoproliferative glomerulonephritis, NS nephrotic syndrome
^a“Other” includes 3 patients with unbiopsied NS

ISSN: 1471-2369